促卵泡激素与枸橼酸氯米芬在不明原因低生育力宫腔内人工授精中的比较:一项随机对照试验
该开放标签多中心随机优效性对照试验在荷兰纳入369对不明原因低生育力夫妇,分别接受75 IU FSH或100 mg CC卵巢刺激,最多4个IUI周期,超过3个优势卵泡时取消周期。FSH组持续妊娠率31%,CC组26%,无显著差异;多胎妊娠率低且两组相似。
要点
- 在严格取消标准下,FSH组持续妊娠率31%,CC组26%,无显著差异。
- FSH组多胎妊娠率1.4%,CC组2.2%,两组均低且无显著差异。
- 严格取消标准是减少IUI多胎妊娠的有效策略。
核心结论
- 在遵循严格取消标准的IUI中,FSH卵巢刺激在累积持续妊娠率方面不优于CC,且多胎妊娠率相似且低。
研究设计与样本
- 荷兰开放标签多中心随机优效性对照试验(NTR 4057),纳入不明原因低生育力夫妇,随机接受75 IU FSH或100 mg CC卵巢刺激,最多4个IUI周期,超过3个优势卵泡时取消周期,按意向性分析。
主要发现
- 2013年7月至2016年3月,369名女性分配至FSH组,369名分配至CC组。
- FSH组113名(31%)获得持续妊娠,CC组97名(26%)获得持续妊娠(RR=1.16,95%CI:0.93-1.47,ARD=0.04,95%CI:-0.02至0.11)。
- FSH组5名(1.4%)发生多胎妊娠,CC组8名(2.2%)发生多胎妊娠(RR=0.63,95%CI:0.21-1.89,ARD=-0.01,95%CI:-0.03至0.01)。
临床怎么用
- 作者认为严格取消标准是减少IUI多胎妊娠的成功解决方案。
- 作者认为选择FSH或CC方案时应考虑费用和患者偏好。
局限性
- 由于干预性质,研究无法设盲。
- 作者认为不太可能引入实施偏倚,因为妊娠结局是客观结局指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Is FSH or clomiphene citrate (CC) the most effective stimulation regimen in terms of ongoing pregnancies in couples with unexplained subfertility undergoing IUI with adherence to strict cancellation criteria as a measure to reduce the number of multiple pregnancies? SUMMARY ANSWER: In IUI with adherence to strict cancellation criteria, ovarian stimulation with FSH is not superior to CC in terms of the cumulative ongoing pregnancy rate, and yields a similar, low multiple pregnancy rate. WHAT IS ALREADY KNOWN: FSH has been shown to result in higher pregnancy rates compared to CC, but at the cost of high multiple pregnancy rates. To reduce the risk of multiple pregnancy, new ovarian stimulation regimens have been suggested, these include strict cancellation criteria to limit the number of dominant follicles per cycle i.e. withholding insemination when more than three dominant follicles develop. With such a strategy, it is unclear whether the ovarian stimulation should be done with FSH or with CC. STUDY DESIGN, SIZE, DURATION: We performed an open-label multicenter randomized superiority controlled trial in the Netherlands (NTR 4057). PARTICIPANTS/MATERIALS, SETTING, METHODS: We randomized couples diagnosed with unexplained subfertility and scheduled for a maximum of four cycles of IUI with ovarian stimulation with 75 IU FSH or 100 mg CC. Cycles were cancelled when more then three dominant follicles developed. The primary outcome was cumulative ongoing pregnancy rate. Multiple pregnancy was a secondary outcome. We analysed the data on intention to treat basis. We calculated relative risks and absolute risk difference with 95% CI. MAIN RESULTS AND THE ROLE OF CHANCE: Between July 2013 and March 2016, we allocated 369 women to ovarian stimulation with FSH and 369 women to ovarian stimulation with CC. A total of 113 women (31%) had an ongoing pregnancy following ovarian stimulation with FSH and 97 women (26%) had an ongoing pregnancy following ovarian stimulation with CC (RR = 1.16, 95% CI: 0.93-1.47, ARD = 0.04, 95% CI: -0.02 to 0.11). Five women (1.4%) had a multiple pregnancy following ovarian stimulation with FSH and eight women (2.2%) had a multiple pregnancy following ovarian stimulation with CC (RR = 0.63, 95% CI: 0.21-1.89, ARD = -0.01, 95% CI: -0.03 to 0.01). LIMITATIONS, REASONS FOR CAUTION: We were not able to blind this study due to the nature of the interventions. We consider it unlikely that this has introduced performance bias, since pregnancy outcomes are objective outcome measures. WIDER IMPLICATIONS OF THE FINDINGS: We revealed that adherence to strict cancellation criteria is a successful solution to reduce the number of multiple pregnancies in IUI. To decide whether ovarian stimulation with FSH or with CC should be the regimen of choice, costs and patients' preferences should be taken into account. STUDY FUNDING/COMPETING INTEREST(S): This trial received funding from the Dutch Organization for Health Research and Development (ZonMw). Prof. Dr B.W.J. Mol is supported by a NHMRC Practitioner Fellowship (GNT1082548). B.W.M. reports consultancy for Merck, ObsEva and Guerbet. The other authors declare that they have no competing interests. TRIAL REGISTRATION NUMBER: Nederlands Trial Register NTR4057. TRIAL REGISTRATION DATE: 1 July 2013. DATE OF FIRST PATIENT’S ENROLMENT: The first patient was randomized at 27 August 2013.
引用
- Danhof NA, van Wely M, Repping S, et al. Follicle stimulating hormone versus clomiphene citrate in intrauterine insemination for unexplained subfertility: a randomized controlled trial. Hum Reprod. 2018. PMID: 30137325. doi:10.1093/humrep/dey268
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。